Want to see SLDB full AI Analyst Report?
SLDB Stock Chart & Stats
$9.89
-$0.15(-1.88%)
At close: 4:00 PM EDT
$9.89
-$0.15(-1.88%)
Day’s Range― - ―
52-Week Range$3.79 - $11.45
Previous CloseN/A
Volume1.09M
Average Volume (3M)879.07K
Market Cap
$1.10B
Enterprise Value$1.08K
Total Cash (Recent Filing)$377.68M
Total Debt (Recent Filing)$20.16M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Nov 11, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding107,225,235
10 Day Avg. Volume818,737
30 Day Avg. Volume879,071
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.74
Price to Sales (P/S)0.00
P/FCF Ratio-3.13
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.17Price Target Upside93.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Balance-Sheet LeverageModest leverage gives Solid greater financial flexibility than a heavily indebted biotech and reduces exposure to interest and refinancing pressure. Although losses remain substantial, the low debt burden leaves more capacity to direct available capital toward clinical development and strategic priorities.
Focused Genetic-Medicine PipelineA focused genetic-medicine strategy can concentrate scientific resources, clinical expertise, and capital around defined high-need disease areas. Its emphasis on next-generation gene therapy and enabling platforms provides a coherent foundation for advancing multiple development opportunities over the coming quarters.
Governance And Oversight ContinuityDirector elections, auditor ratification, and shareholder support for current leadership provide continuity during an important clinical-development period. Stable governance and established financial oversight can support consistent execution of the pipeline and future financing or strategic decisions.
Bears Say
No Current Commercial RevenueThe absence of current revenue leaves Solid dependent on clinical progress, partnerships, financing, or eventual approvals to create an operating income stream. This makes near-term financial performance highly sensitive to development outcomes and limits internal funding for continued research.
Worsening Operating LossesExpanding losses indicate that operating costs remain far ahead of commercial income and that profitability is not yet supported by the business model. Persistent losses can consume equity and increase the amount of external capital required before the pipeline produces meaningful revenue.
Heavy Cash Burn And Dilution RiskThe scale and worsening trend of cash burn imply continued reliance on external funding unless spending moderates or revenue emerges. Equity financing can extend development runway, but repeated share issuance and the expanded offering capacity may dilute existing shareholders.
Solid Biosciences News
SLDB FAQ
What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $3.79 and its highest was $11.45 in the past 12 months.
What is Solid Biosciences’s market cap?
Solid Biosciences’s market cap is $1.10B.
When is Solid Biosciences’s upcoming earnings report date?
Solid Biosciences’s upcoming earnings report date is Nov 11, 2026 which is in 62 days.
How were Solid Biosciences’s earnings last quarter?
Solid Biosciences released its earnings results on Aug 06, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.462 by $0.082.
Is Solid Biosciences overvalued?
According to Wall Street analysts Solid Biosciences’s price is currently Undervalued.
Does Solid Biosciences pay dividends?
Solid Biosciences does not currently pay dividends.
What is Solid Biosciences’s EPS estimate?
Solid Biosciences’s EPS estimate is -0.41.
How many shares outstanding does Solid Biosciences have?
Solid Biosciences has 107,225,235 shares outstanding.
What happened to Solid Biosciences’s price movement after its last earnings report?
Solid Biosciences reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.462. Following the earnings report the stock price went down -3.674%.
Which hedge fund is a major shareholder of Solid Biosciences?
Currently, no hedge funds are holding shares in SLDB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solid Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.17 (93.80% Upside)
$19.17 (93.80% Upside)
Blogger Sentiment
Bullish
SLDB Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
93.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
36.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Solid Biosciences
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
SLDB Stock 12 Month Forecast
Average Price Target
$19.17
▲(93.80% Upside)
Technical Analysis
Ownership Overview
12.09% Insiders
9.98% Mutual Funds
62.60% Other Institutional Investors
2.74% Public Companies and
Individual Investors